RRP1B (ribosomal RNA processing 1 homolog B) was first identified as a metastasis susceptibility gene in breast cancer through its ability to modulate gene expression in a manner that can be used to accurately predict prognosis in breast cancer. However, the mechanism(s) by which RRP1B modulates gene expression is currently unclear. Many RRP1B binding candidates are involved in alternative splicing, a mechanism of gene expression regulation that is increasingly recognized to be involved in cancer progression and metastasis. One such target is SRSF1 (serine/arginine-rich splicing factor 1) (SF2/ASF, splicing factor 2/alternative splicing factor), an essential splicing regulator that also functions as an oncoprotein. Earlier studies demonstrated that splicing and transcription occur concurrently and are coupled processes. Given that RRP1B regulates transcriptional activity, we hypothesized that RRP1B also regulates the expression of alternative mRNA isoforms through its interaction with SRSF1. Interaction between RRP1B and SRSF1 was verified by coimmunoprecipitation and coimmunofluorescence. Treatment of cells with transcriptional inhibitors significantly increased this interaction, demonstrating that the association of these two proteins is transcriptionally regulated. To assess the role of RRP1B in the regulation of alternative isoform expression, RNA-sequencing data were generated from control and Rrp1b-knockdown cells. Knockdown of Rrp1b induced a significant change in isoform expression in over 600 genes compared with control cell lines. This was verified by quantitative reverse-transcription PCR using isoform-specific primers. Pathway enrichment analyses identified cell cycle and checkpoint regulation to be those most affected by Rrp1b knockdown. These data suggest that RRP1B suppresses metastatic progression by altering the transcriptome through its interaction with splicing regulators such as SRSF1.
INTRODUCTION
RRP1B (ribosomal RNA processing 1 homolog B) was first identified as a metastasis susceptibility gene through expression quantitative trait locus analysis of polyoma middle-T transgeneinduced mammary tumors. Studies of these tumors revealed that the expression of Rrp1b highly correlated with the expression of extracellular matrix genes. 1 Abnormal regulation of extracellular matrix genes is commonly observed in human and mouse tumors, and serves a predictive signature of metastases. 2, 3 Microarray analyses demonstrated that ectopic expression of Rrp1b in mouse mammary tumor cell lines has profound effects on global gene expression. In addition, an expression signature generated from these microarray data accurately predicted overall survival in multiple breast cancer patient data sets. 1 Finally, the importance of this gene as a germline suppressor of tumor progression and metastasis in human breast cancer was further underscored by the observation that a non-synonymous coding polymorphism in RRP1B (1421C4T; P436L; rs9306160) is reproducibly associated with metastasis-free survival in multiple human breast cancer cohorts. 1, 4 Human RRP1B is composed of 758 amino acids, and contains an amino-terminal NOP52 domain and three nuclear localization signals located near the carboxy-terminus. Mouse RRP1B is 724 amino acids long and shares 62% sequence similarity with human RRP1B. RRP1B interacts with chromatin as well as rRNA transcripts, and its localization is almost entirely nuclear, with the majority of RRP1B being found in the nucleolus. 5, 6 The mechanism underlying the functions of RRP1B largely remains to be identified. Characterization of potential binding candidates of RRP1B through tandem affinity purification and mass spectrometry provided some insight on this matter. 5 A large number of these candidates were involved in alternative mRNA splicing, two prominent examples, of which are SRSF1 (serine/arginine-rich splicing factor 1) (SF2/ASF, splicing factor 2/alternative splicing factor) and CROP. SRSF1 is an essential splicing regulator that assists in the formation of the spliceosome by binding with U1 small nuclear ribonucleoprotein, 7 and influences the selection of alternative splice sites. 8, 9 CROP is the human homolog of yeast Luc7p, which is an essential component of yeast U1 small nuclear ribonucleoprotein, 10 and it has been shown to interact with SRSF1 through yeast two-hybrid assays. 11 Alternative mRNA splicing is an essential method of regulating eukaryotic gene expression, in which a single pre mRNA is subsequently spliced to generate various transcripts yielding different protein products. Cells or tissues control alternative splicing in response to different physiological states. Dysregulation of mRNA splicing in most cases leads to severe diseases, including cancer. 12 In cancerous tissues, it was found that the level of mRNA splicing and the number of transcript variants are comparable to those of normal tissues. 13 Yet, neoplastic tissues do express an altered transcriptome characterized by tumor-specific isoforms. [14] [15] [16] It is unclear whether this is a direct cause or a secondary effect of tumor progression. 17 The aim of this study is to examine whether RRP1B has a role in regulating mRNA splicing. RNA-sequencing (RNA-seq) was performed to measure changes in isoform expression in response to Rrp1b knockdown, and biochemical approaches were used to assess the interaction of RRP1B and additional proteins involved in splicing. RRP1B was confirmed to interact with the splicing regulator SRSF1 and spliceosomal protein CROP. Knockdown of Rrp1b increased the metastatic activity of mouse mammary tumor cells and caused a significant change in isoform expression in 658 different genes. On the basis of these findings, we conclude that RRP1B functions as a metastasis suppressor by regulating gene expression, most likely at the mRNA level.
RESULTS

RRP1B interacts with the splicing regulator SRSF1
The splicing regulator and oncoprotein SRSF1
18 was identified as a potential binding factor of RRP1B. 5, 6 Coimmunoprecipitation of endogenous RRP1B and SRSF1 was confirmed in MDA-MB-231 cells ( Figure 1a) . Colocalization of the two proteins was observed in speckles in the nucleus of cells overexpressing wild-type RRP1B (Figure 1b) . To identify the region of RRP1B that interacts with SRSF1, 293T cells were transfected with a series of HA-tagged RRP1B deletion constructs; DN (D9-220), in which the highly conserved NOP52 domain was deleted, DMID (D221-435), which does not have the middle region containing the first nuclear localization signal, and DC (D452-749), in which the two nuclear localization signals in the C-terminus were deleted. 5 Interaction with SRSF1 that was observed with wild-type RRP1B was lost upon deletion of the C-terminus of RRP1B, implying that this portion of RRP1B mediates the interaction between these two proteins ( Figure 1c ). However, deletion of the C-terminus of RRP1B has been shown to disrupt its localization and cause partial redistribution into the cytoplasm. 5 Therefore, although a significant amount remains in the nucleus, the loss of interaction between RRP1B and SRSF1 observed with the DC construct might be due, in part, to the redistribution of RRP1B to the cytoplasm.
In addition to SRSF1, RRP1B was found to interact with another factor involved in splicing, the spliceosomal protein CROP (Figures  1c and d) . Coimmunoprecipitation patterns of CROP with RRP1B were similar to that of SRSF1, where interaction was lost with the deletion of the C-terminus, but not with the deletion of the N-terminus (Figure 1c ).
The interaction between RRP1B and SRSF1 is transcriptionally regulated Many studies have shown that transcription and splicing occur concurrently, and that their mutual progression is highly intertwined. [19] [20] [21] [22] [23] With this in mind, and given the fact that RRP1B is a critical regulator of metastasis-related transcriptional programs, 1 we hypothesized that the interaction between RRP1B and SRSF1 is transcriptionally dependent. To test this hypothesis, transcription in MDA-MB-231 cells was inhibited using either 5,6-Dichloro-1-b-D-ribofuranosylbenzimidazole (DRB) or Actinomycin D (Act D). DRB inhibits transcription by binding near the ATP binding site of CDK9, 24 an essential kinase subunit of positive transcription elongation factor. Act D is a DNA intercalator that inhibits transcription by interfering with the progression of RNA polymerase. 25 In cells treated with 25 mg/ml DRB or 2.5 mg/ml and 5 mg/ml Act D, interaction between endogenous RRP1B and SRSF1 increased significantly compared with control ( Figure 2a, lane 1-4 ). These concentrations inhibit transcription mediated by RNA polymerase I and II when added to the medium. 26 Longer DRB treatment increased the degree of interaction between the two proteins ( Figure 2a, lane 5, 6 ). This increase in interaction was confirmed through immunofluorescence as well, where colocalization of endogenous RRP1B and SRSF1 occurred in larger aggregates within the nuclei with 2 h DRB treatment (Figure 2b ). We also observed redistribution of RRP1B from the nucleoli to the nucleoplasm with DRB treatment, which causes disruption of the nucleoli, as previously described. 6 As the two inhibitors, DRB and Act D, function through distinct pathways to inhibit transcription, it is most likely that the interaction between RRP1B and SRSF1 is affected downstream of the transcriptional process, rather than through a common upstream pathway.
Knockdown of Rrp1b increases cell invasiveness in vitro and metastasis in vivo The effects of stable short hairpin RNA-mediated knockdown of Rrp1b were examined in the highly metastatic mouse mammary tumor cell lines Mvt-1 27 and 4T1. 28 For the Mvt-1 cell line, clonal isolates were selected by serial dilution. RRP1B knockdown in both Mvt-1 clones and 4T1 cells was confirmed by quantitative reverse transcription-PCR (qRT-PCR) and western blotting (Figures 3a and  b) . Knockdown of RRP1B caused an increase in cell proliferation in both cell lines in culture (Figures 3c and d) . When injected into the mammary fat pads of syngenic FVB/NJ mice, Rrp1b knockdown in the Mvt-1 cell line significantly reduced primary tumor burden, and produced an Bsixfold increase in pulmonary surface metastasis compared with controls ( Figure 3e ). This increase in metastasis with Rrp1b knockdown was reproduced with the orthotopic injection of the 4T1 cell cultures into the mammary fat pads of syngenic BALB/c mice (Figure 3f ). To examine in vitro cell invasiveness, Mvt-1 clonal isolates were plated in control or Matrigel chambers. With overnight incubation, Rrp1b-knockdown cell lines displayed an average twofold increase in invasion compared with control ( Figure 3g ). In addition, Rrp1b-knockdown cell lines formed more colonies in soft agar compared with control, demonstrating an increase in anchorage-independent cell growth (Figures 3h and i) . Increase in cell proliferation and cell invasiveness was observed with the human breast carcinoma MDA-MB-231 cell line as well (Supplementary Figure S1) . Such changes in cell behavior are likely either primary events or secondary to the in vitro increase in cell proliferation rate following Rrp1b knockdown.
RNA-seq analysis demonstrates that knockdown of Rrp1b induces differential gene and isoform expression On the basis of the metastatic activity observed in vivo, duplicate control and Rrp1b-knockdown Mvt-1 clonal isolate cell lines were selected for RNA-seq. Gene expression analysis of the RNA-seq data demonstrated that 615 genes displayed significant changes in transcript levels following Rrp1b knockdown, with 362 upregulated and 253 downregulated genes at a qp0.05 genome-wide significance level ( Figure 4a , Supplementary Table  S1 ). Pathway enrichment analysis using Ingenuity Pathway Analysis (IPA, www.ingenuity.com) indicated that cell cycle regulation was a major function of these genes affected by Rrp1b expression (Table 1) .
To examine the role of RRP1B in the regulation of alternative isoforms, we analyzed differential isoform expression between control and knockdown cell lines. Similar to the results seen in gene expression, a substantial difference was observed in isoform expression; 699 isoforms, representing 658 different genes, were identified as having a significant change in the expression with Rrp1b knockdown (Figure 4b , Supplementary Table S2) . Four hundred and ninety seven of the 699 isoforms displayed differential gene expression, with the remaining 202 isoforms not being identified in the aforementioned gene expression analysis ( Figure 4c ). The locations of isoform-specific exons were profiled by comparing them to a transcript constructed in silico that included all exons from annotated isoforms. These data demonstrated that the majority of differential exons regulated by RRP1B are located internally between the first and last exon. Changes in the first exon may be due to differential promoter utilization, whereas changes in internal exons indicate true differences in mRNA splicing. For all 699 isoforms profiled, 59% of differential exons were located internally within the transcript (for example, Tapbp-001 exon 3; Figure 5 ), 27.2% were in the 5 0 region or the first exon (for example, Arl8a-001 exon 1; Figure 5 ), and 13.8% were in the 3 0 region or the last exon. Pathway enrichment analysis was performed to gain more insight on the isoforms affected by Rrp1b knockdown. Depending on the number of molecules identified to support each pathway, there was some variation in the significance (determined by Figure 4 . Rrp1b knockdown causes a significant change in global gene and isoform expression. (a) A heatmap of differentially expressed genes from RNA-seq data in control and Rrp1b-knockdown stable cell lines. (b) Differential isoform expression in control and Rrp1b-knockdown stable cell lines. A heat map was generated to display the ratio of isoforms that were upregulated in the control and/or upregulated in the knockdown cell lines for each gene. Note the middle section, shown in a light blue color across both sets, has a ratio of 0.5 for the control and the knockdown cell lines, indicating a complete switch in isoform expression. (c) A total of 497 genes overlapped between the differential gene expression analysis and differential isoform expression analysis.
Benjamini-Hochberg correction of P-values) of each pathway between the gene and isoform expression. For example, p53 signaling ranked as the fourth most significant pathway in the gene analysis with a À log(B-H P-value) of 3.73, whereas it ranked ninth in the isoform analysis with a -log(B-H P-value) of 3.59. Despite these differences in P-values, the majority of the Figure 5 . Validation of isoform-specific regulation by RRP1B via qRT-PCR. RNA from control and Rrp1b-knockdown stable Mvt-1 cell lines was used for qRT-PCR. Isoform-specific regions were selected for target genes identified through RNA-seq analysis. For each gene, the top isoform was identified by RNA-seq to have a significant fold-change in expression with Rrp1b knockdown. Primers were designed so that at least one primer extended across an exon junction. Exons are depicted in relation to their genomic location.
significant pathways, which was determined by a -log(B-H P-value) of 1.30 or higher (P-valuep0.05), overlapped between the two analyses. The top pathways for differential gene and isoform expression analyses are shown in Tables 1 and 2 , respectively. As was the case with the gene expression analyses, the most highly represented molecular and cellular functions and pathways were those involved in cell cycle and checkpoint regulation (Table 2) . Surprisingly, the differentially expressed isoforms were not of genes involved in pathways involved in alternative mRNA splicing. Among the 54 splicing-related factors screened, 29 which included heterogeneous nuclear ribonucleoproteins and serine/arginine-rich proteins, only two genes, Hnrnph2 30,31 and Srsf5 (Srp40) 32,33 were identified to have differential isoform expression with the knockdown of Rrp1b. Thus, the large scale change in isoform expression observed with Rrp1b knockdown is likely a direct effect of RRP1B itself, rather than a secondary effect caused by the factors regulated by RRP1B.
To confirm the differential regulation of alternative isoforms by RRP1B, qRT-PCR expression analysis was performed with Mvt-1 control and Rrp1b-knockdown samples. Isoform-specific primers were designed to either extend across a unique exon junction or lie within an isoform-specific exon ( Figure 5, arrows) . For instance, for Tubb5-001 and Tubb5-003, the junction region spanning between exon 1 and 2 is unique for each isoform as the sequence for exon 2 differs between the two isoforms. For expression analysis, two isoforms were selected for each gene with one isoform being identified by RNA-seq as being dysregulated by Rrp1b knockdown ( Figure 5 , top isoform) and the other having no significant change ( Figure 5 , bottom isoform). These analyses confirmed that Rrp1b regulates gene expression in an isoformspecific manner. Splicing patterns vary greatly across different species and tissues, 34 and the level of conservation for orthologous genes ranges from 11 to 20%. [35] [36] [37] To see whether the change in splicing observed with Rrp1b knockdown was cell line specific, the expression of the isoforms in Figure 5 was also examined in clonal isolates of stable 4T1 Rrp1b-knockdown cells, and compared with that of the Mvt-1 cell lines (Supplementary Figure S2) . Many of the isoforms changed expression in the same direction with similar Log(fold change) values, while a few of them, such as Arl8a-003 and Rpa2-001, demonstrated divergent expression patterns. This variation is not unexpected given the different genetic background of the two cell lines. Further, it is unlikely that these minor differences in splicing have a significant impact upon metastasis as knockdown of Rrp1b in both Mvt-1 and 4T1 cell lines resulted in very similar in vitro and in vivo behaviors.
DISCUSSION
With the discovery of the diverse functions of RNA transcripts, increasing interest has been placed upon the role of alternative splicing in tumor progression. Although neoplastic tissues have been reported to display a perturbation in mRNA isoform expression compared with matched normal tissues, [14] [15] [16] ,38 the precise role of this altered transcriptome and splicing pattern in tumorigenesis remains uncertain. Previously, it was shown that the metastasis suppressor Nm23-H1 regulates changes in the expression of RNA post-transcriptional modification proteins, including Gemin5, a component of the spliceosome. 39 Yet, a direct role for metastasis modifiers in splicing has not yet been reported, although it seems that many factors involved in splicing have a variety of cellular functions. 40 Here, using RNA-seq in Abbreviations: EIF2, eukaryotic initiation factor 2; HER-2, human epidermal growth factor receptor 2; VDR/RXR, vitamin D receptor/retinoic acid X receptor.
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combination with other biochemical methods, the metastasis modifier RRP1B has been demonstrated to directly regulate alternative isoform expression. This suggests that alternative splicing, and the diverse isoforms generated from that process, may have a role in the regulation of various factors implicated in metastasis.
Alternative mRNA splicing is a fundamental cellular mechanism involved in the regulation of gene expression, and it has been reported that the majority of human genes is alternatively spliced to express different isoforms. 41 It is a precisely regulated process that consists of specific splice recognition sites, splicing machinery and other regulatory factors. Defects in splicing can occur at any stage of the process, and have been shown to be features of a wide-range of diseases, including cancer. As alternative splicing is a tightly-regulated process, mutations in most, but not all, splicing factors result in a change in splicing patterns. 42 In addition, many studies demonstrate that relatively few genes have altered splicing patterns in primary tumor tissue compared with matched normal tissue. 43, 44 Considering these facts, the fundamental question posed by our research is whether the metastasis modifier RRP1B is modulating cellular splicing patterns. Our data does indeed indicate that this is the case as our analysis of the transcriptome of the highly metastatic Mvt-1 cell line clearly demonstrates that Rrp1b knockdown induces widespread changes in isoform expression. Specifically, the majority of the isoform-specific exons induced by knockdown of Rrp1b were found to be located internally within the mature mRNA. Given that splicing is used to generate different mature mRNA isoforms from the same pre mRNA, we argue that these changes in internal exon composition upon Rrp1b knockdown can only arise due to changes in splicing regulation. In addition, interaction between RRP1B and the splicing regulator SRSF1, as well as with spliceosomal protein CROP (Figure 1) , supports the direct involvement of RRP1B in splicing, rather than indirect regulation of splicing, such as that of Nm23-H1. 39 We would, however, like to stress that the mechanism of action of RRP1B is likely not entirely dependent on its role in splicing regulation. In particular, we acknowledge that a sizable proportion of the isoform-specific exons expressed as a consequence of Rrp1b knockdown are located at the 5 0 region of the transcript. Expression of these isoforms has likely been induced through the utilization of alternative promoters. Our previous work has demonstrated that RRP1B interacts with a variety of chromatinassociated factors. Therefore, expression of this type of isoform with alternative 5 0 exons is likely a consequence of RRP1B interacting with these chromatin-associated binding partners rather than splicing regulators.
An extensive study on the nuclear protein interactome of RRP1B by Chamousset et al. 6 found that it was enriched with ribosomal subunit proteins, particularly those of the large subunit. This suggests that RRP1B has an important role in cell growth and metabolism, as the ribosome is regulated in response to signals controlling these pathways. A large number of genes encoding components of both the 60S large and 40S small ribosomal subunits displayed differentially expressed isoforms with the knockdown of Rrp1b. Interestingly, all of the dysregulated components of the small ribosomal subunit except for Rps19, as well as 7 of the 12 dysregulated large ribosomal subunit genes were those encoding the previously identified components of the RRP1B protein interactome (highlighted in Supplementary Table  S2 ). This demonstrates that RRP1B not only interacts with ribosomal protein subunits in the nucleus, but also controls their expression. Not surprisingly, the cellular pathways most affected by the knockdown of Rrp1b were those involved in cell cycle regulation. Collectively, these findings suggest a greater role for RRP1B as a regulator of cell growth than previously reported, which explains the significant change in in vitro cell proliferation observed here.
Many studies demonstrate that splicing and transcription occur concurrently, rather than sequentially, and that splicing is affected by the rate and progression of transcription, which is affected by events at the chromatin, such as histone modification. [19] [20] [21] [22] [23] An earlier study that identified potential binding factors of RRP1B through tandem affinity purification found that these proteins can be largely classified as either chromatin-associated or splicingrelated factors, and confirmed RRP1B interaction with chromatinassociated factors. 5 In addition, we observed interaction between RNA polymerase II and RRP1B through coimmunoprecipitation (Supplementary Figure S3) . These studies combined with our findings here suggest a role for RRP1B as a mediator between the transcription complex and splicing factors (Figure 6 ), and that differential levels of RRP1B impacts the transcriptome, and ultimately metastasis. To our knowledge, this study is the first to directly link a metastasis modifier to regulation of alternative splicing machinery and subsequent alterations in cellular mRNA splicing patterns. 
MATERIALS AND METHODS
Generation of stable RRP1B-knockdown cell lines
For Rrp1b knockdown in the Mvt-1 and 4T1 cell lines, a short hairpin RNA targeting mouse Rrp1b inserted into the pSuper.retro.puro vector (OligoEngine, Seattle, WA, USA) was transfected along with retroviral packaging vectors. Mvt-1 and 4T1 cells expressing the vector were selected in 10 mg/ml or 5 mg/ml of puromycin, respectively. Stable RRP1B-knockdown cells were also established in MDA-MB-231 cells using short hairpin RNA targeting human RRP1B. Knockdown at the protein level was confirmed using polyclonal antibodies against RRP1B. 6 Oligo sequences for short hairpin RNAs are provided in Supplementary Table S3. RNA isolation and qRT-PCR Total RNA was isolated from cells using the RNeasy mini kit (QIAGEN) following manufacturer's protocol with a 15 min DNase treatment before elution. RNA concentration was measured using NanoDrop (Wilmington, DE, USA), and 1 mg of total RNA was used per reverse transcription reaction in a final volume of 20 ml. Reverse transcription was performed using complementary DNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). The obtained complementary DNA was then diluted 10-fold and 1 ml was used Figure 6 . RRP1B acts as a mediator between chromatin-associated transcription factors and splicing regulators. Previous studies and our results shown here collectively suggest a role for RRP1B at the chromatin as a mediator between transcription and splicing factors to regulate mRNA expression.
for each 5 ml real-time PCR reaction. Primers used for qRT-PCR are provided in Supplementary Table S3. Coimmunoprecipitation and western blotting For coimmunoprecipitation, cells in 100-mm plates were collected with 250 ml 1X lysis buffer (600 mM NaCl, 0.2 mM EGTA, 40 mM Tris pH 7.4, 4 mM MgCl 2 , 2% Triton-X). After 30 min incubation on ice, samples were centrifuged at 14 000 g at 4 1C for 5 min. From each sample, 5 ml of the supernatant was removed as Input, and the balance was diluted to a final volume of 800 ml and incubated with rotation at 4 1C with one of the following antibodies: anti-HA (Roche, Indianapolis, IN, USA) for HA-tagged RRP1B constructs, anti-RRP1B (Sigma, St Louis, MO, USA) for endogenous RRP1B or immunoglobulin G (Millipore, Billerica, MA, USA) as a negative control. After 2 h, 20 ml of DynaBeads (Invitrogen, Grand Island, NY, USA) washed and resuspended in 1X lysis buffer were added to each immunoprecipitation and incubated with rotation overnight at 4 1C. The following day, samples were washed with 1X lysis buffer and resuspended in 2X sample buffer. Samples were separated on a 4-12% Bis-Tris gel (Invitrogen).
Immunofluorescence and microscopy 
Orthotopic mammary fat pad injection
Female FVB/NJ and BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Injections and metastasis assays were performed as previously described. 1 Briefly, 1 Â 10 5 cells in 100 ml saline were orthotopically implanted into the mammary fat pads of 6 to 8-week-old female mice. Lungs and tumors were collected 4 weeks later. All animal experiments were performed in compliance with the National Human Genome Research Institute Animal Care and Use Committee's guidelines.
Soft agar and Matrigel invasion assays
For soft agar assays, Mvt-1 and 4T1 cells were plated at 2 Â 10 3 cells per 24-well in 0.33% agar, and incubated for 7 days. MDA-MB-231 cells, 4 Â 10 3 cells were plated in 0.33% agar in 24-well plates and allowed to grow for 15 days until significant colony formation was observed. Cells were then stained with 0.005% crystal violet for colony counting. For Matrigel invasion assays, control and Rrp1b-knockdown stable Mvt-1 cell lines were plated at 7.5 Â 10 3 cells per 24-well control Transwell or Matrigel invasion chambers (BD Biosciences, San Jose, CA, USA) in Dulbecco's Modified Eagle Medium 0% fetal bovine serum and chambers were placed in Dulbecco's Modified Eagle Medium 10% fetal bovine serum. Chambers were collected and stained with crystal violet the next day for counting.
RNA-seq
For mRNA library construction, mRNA from 10 mg of total RNA was poly-A selected using Dynal Oligo (dT) beads (Invitrogen) and sheared to B400 b using Covaris S2. The sample was concentrated to 25 ml using an Amicon Ultra 20K filter. Reverse transcription was performed using random hexamers and SuperScript Double-Stranded complementary DNA Synthesis Kit (Invitrogen). A library was constructed from the resulting complementary DNA according to the Illumina protocol in the PairedEnd DNA Sample Prep Oligo Only Kit. All additional enzymes were purchased from New England Biolabs (Ipswich, MA, USA) with the exception of Platinum Pfx (Invitrogen). After paired-end adapter ligation, the sample was size selected on a 2% agarose gel. Test amplification was performed by removing aliquots of a PCR reaction every 2 cycles from 4-16 cycles to insure that the library was not over amplified. These aliquots were evaluated on a 2% agarose gel and an optimal cycle number was selected for subsequent large scale amplification. Amplification reactions were cleaned up using two rounds of Agencourt AMPure Beads (Beckman Colter, Indianapolis, IN, USA). Libraries were quantitated by qPCR using Power Sybr Green PCR Master Mix (Applied Biosystems, Grand Island, NY, USA). Libraries were sequenced on the Illumina GAIIx platform using ver. 4 chemistry to obtain 76-base-paired reads. Data were processed using RTA1.8.70.0 and CASAVA 1.7.0. Those reads that passed the Illumina platform quality check were kept for downstream analyses.
RNA-seq transcript assembly and identification of differentially expressed genes and isoforms A reference genome-guided strategy was used to assemble transcripts from the RNA-seq data. Sequence reads were aligned to the mouse genome (mm9; downloaded from ENSEMBL) using TopHat (v. 1.2.0) 45 with the following parameters: -p 3; -m 2; -r 348; -G (general transfer format (GTF) of protein-coding transcripts downloaded from ENSEMBL (e64)). TopHat alignments were supplied to Cufflinks (v. 1.1.0) 46 for transcript assembly using the following parameters: -p 6; -N (upper quartile normalization); -b (mm9 genome FASTA sequence for bias correction); -M (GTF from ENSEMBL (e61) of rRNA, tRNA and mtRNA genomic locations for masking); GTF of protein-coding transcripts from ENSEMBL (e64). Differentially expressed genes and transcripts were identified using Cuffdiff (v. 1.1.0) with the following parameters: -p 6; -N (upper quartile normalization); -b (mm9 genome fasta sequence for bias correction 47 ); -M (GTF of rRNA, tRNA and mtRNA genomic locations for masking); GTF of protein-coding transcripts from ENSEMBL (e64). Genes and isoforms having a q-valuep0.05 were considered differentially expressed, as reported in the gene_exp.diff and isoform_exp.diff output files from Cuffdiff. Pathway enrichment was analyzed using IPA (Ingenuity Systems, Redwood City, CA, USA) using a Benjamini-Hochberg correction on Pvalues generated from a Fisher's Exact test.
To determine the frequency at which the first exon, internal exons or the last exon of a gene is alternatively expressed, a primary transcript was constructed in silico that included all exons from the annotated isoforms (ENSEMBL e64) for a given protein-coding gene. The differentially expressed isoforms were compared with these primary transcripts for differences in the ENSEMBL-annotated genomic positions of exon start and stop locations. A record was kept if differences in exon usage and/or exon junction positions occurred in the initial 5 0 exon (first exon), final 3 0 exon (last exon) or an exon that is not the initial 5 0 or final 3 0 exon (internal).
